Light Horse Therapeutics Secures $62M Series A Funding and Partners with Novartis for Cancer Therapies

Funding and Partnership:
Light Horse Therapeutics has secured $62M in Series A funding and entered into a multi-target partnership with Novartis to develop therapies for cancer treatment12.

Investors:
The Series A funding was led by Versant Ventures and included Mubadala Capital, Bristol-Myers Squibb Co, Taiho Ventures, and AbbVie1.

Partnership Terms:
The partnership with Novartis includes $25M upfront, $1B in research, development, and sales milestones, plus royalties on licensed therapeutics2.

Technology:
Light Horse Therapeutics uses a proprietary precision genetic editing platform to identify novel functional domains in disease-critical targets, turning conventional drug discovery on its head with a function-first approach1.

Leadership:
The company is led by CEO Markus Renschler, with a team including Thomas Daniel, MD (Chairman), Laure Escoubet, PhD (CSO), and scientific co-founders Brian Liau, PhD, Ben Cravatt, PhD, and Nathanael Gray, PhD1.

Sources:

1. https://www.finsmes.com/2025/01/light-horse-therapeutics-raises-62m-in-series-a-financing.html

2. https://pharmashots.com/20608/light-horse-therapeutics-partners-with-novartis-to-discover-therapies-for-cancer-treatment